Edap Tms Sa (NASDAQ:EDAP) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Tuesday. The brokerage currently has a $3.25 price target on the stock. Zacks Investment Research’s price target indicates a potential upside of 14.04% from the company’s current price.

According to Zacks, “EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors. “

Several other research firms have also recently commented on EDAP. TheStreet upgraded shares of Edap Tms Sa from a “sell” rating to a “hold” rating in a report on Tuesday, September 27th. HC Wainwright restated a “buy” rating on shares of Edap Tms Sa in a report on Tuesday, August 30th.

Shares of Edap Tms Sa (NASDAQ:EDAP) traded up 4.78% on Tuesday, hitting $2.85. 112,415 shares of the stock traded hands. Edap Tms Sa has a 12-month low of $2.43 and a 12-month high of $6.57. The stock has a market cap of $81.87 million, a price-to-earnings ratio of 17.38 and a beta of 1.12. The stock has a 50-day moving average price of $2.92 and a 200 day moving average price of $3.26.

Edap Tms Sa (NASDAQ:EDAP) last announced its earnings results on Thursday, August 25th. The company reported $0.09 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.12. Edap Tms Sa had a net margin of 11.53% and a return on equity of 58.61%. On average, analysts anticipate that Edap Tms Sa will post $0.16 earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in Edap Tms Sa stock. Perkins Capital Management Inc. acquired a new stake in shares of Edap Tms Sa (NASDAQ:EDAP) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 118,000 shares of the company’s stock, valued at approximately $391,000. Perkins Capital Management Inc. owned about 0.46% of Edap Tms Sa as of its most recent SEC filing. 12.11% of the stock is currently owned by institutional investors and hedge funds.

Edap Tms Sa Company Profile

EDAP TMS SA (EDAP) is a holding company engaged in developing and marketing the Ablatherm and Focal One devices. The Company operates two divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) (including lithotripsy activities). The Company is developing HIFU technology for the treatment of certain other types of tumors.

5 Day Chart for NASDAQ:EDAP

Receive News & Stock Ratings for Edap Tms Sa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms Sa and related stocks with our FREE daily email newsletter.